{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:27:54Z","timestamp":1780090074835,"version":"3.54.0"},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Activation of tumour necrosis factor receptor 1 (TNFR1) promotes inflammation in several autoimmune diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate safety, tolerability and clinical efficacy of balinatunfib versus placebo in patients with mild\u2010to\u2010moderate psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Phase\u20101, 4\u2010week, randomized, double\u2010blind, placebo\u2010controlled pilot study, including patients aged 18\u201365\u2009years with chronic plaque\u2010type psoriasis with mild\u2010to\u2010moderate severity as defined by Psoriasis Area Severity Index (PASI \u226416) and\u2009\u22652 lesions with a Target Lesion Severity Score (TLSS) \u22654 at both screening and baseline. The primary endpoint was safety and tolerability of balinatunfib as assessed by the incidence of adverse events (AEs), treatment\u2010emergent AEs (TEAEs) and AEs of special interest. Secondary endpoints were the percent change in TLSS from baseline to Weeks 2 and 4. Serum biomarkers, interleukin\u201022 (IL\u201022), IL\u201017F and percent change in PASI from baseline to Weeks 2 and 4, were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      38 male patients (age [mean\u2009\u00b1\u2009SD], 43\u2009\u00b1\u200910.6) were randomized to receive 200\u2010mg balinatunfib (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200926) or placebo (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200912). No serious or severe TEAEs or adverse events of special interest were observed during the study. Dysgeusia (61.5% vs. 0%) and nausea (19.2% vs. 0%) were the most frequently reported TEAEs in the balinatunfib versus the placebo groups. Balinatunfib showed improvements from baseline in TLSS vs. placebo at Week 2 (17.06% vs. 6.29%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.032) and Week 4 (38.18% vs. 20.44%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012). Exploratory analyses suggested an improvement in the total PASI scores at Week 2 (17.73% vs. 4.12%, nominal\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005), Week 4 (35.09% vs. 15.71%, nominal\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009) and decreased serum levels of IL\u201022 (nominal\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0001) and IL\u201017F (nominal\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0025) with balinatunfib treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with mild\u2010to\u2010moderate psoriasis treated with balinatunfib reported no severe or serious TEAEs and showed promising clinical responses, suggesting that further evaluation of TNFR1 signal inhibition in inflammatory diseases is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.70262","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:24:55Z","timestamp":1770830695000},"page":"1030-1039","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phase 1 study of balinatunfib, an oral inhibitor of TNFR1 signal in mild\u2010to\u2010moderate psoriasis"],"prefix":"10.1111","volume":"40","author":[{"given":"Nassr","family":"Nassr","sequence":"first","affiliation":[{"name":"Sanofi  Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohn A.","family":"Chow","sequence":"additional","affiliation":[{"name":"Sanofi  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai Anh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Sanofi  Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Perrin","sequence":"additional","affiliation":[{"name":"Sanofi  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Schumacher","sequence":"additional","affiliation":[{"name":"Sanofi  Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank\u2010Dietrich","family":"Wagner","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Research Organisation  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dreis","sequence":"additional","affiliation":[{"name":"Sanofi  Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amel","family":"Lahmar","sequence":"additional","affiliation":[{"name":"Sanofi  Morristown New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Kohlmann","sequence":"additional","affiliation":[{"name":"Sanofi  Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Wiekowski","sequence":"additional","affiliation":[{"name":"Sanofi  Morristown New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2864-8207","authenticated-orcid":false,"given":"Tiago R.","family":"Matos","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Centers, University of Amsterdam  Amsterdam Netherlands"},{"name":"Sanofi  Amsterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00630-5"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13854"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.340"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05663"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052719"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01002-7"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.585880"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2011.09.004"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00460"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200635921"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00639-6"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.208"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.2MA0121-082R"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.157.7.3178"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1037983"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13616-1"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20828-3"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.07.040"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000119415"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.05.040"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3655"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16020239"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16010111"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03562.x"},{"issue":"2","key":"e_1_2_14_26_1","first-page":"167","article-title":"Psoriasis: severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severity","volume":"16","author":"Kerkhof PC","year":"2006","journal-title":"Eur J Dermatol"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13317-013-0057-4"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804595"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S240891"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12946"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70262","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70262","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:50:37Z","timestamp":1779695437000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1111\/jdv.70262"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70262","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"2025-06-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}